NEW YORK (GenomeWeb News) – Wasatch Microfluidics is in the process of raising $1 million in a Series B round that is expected to close within the next three weeks, its president said.

Earlier this week, Pasadena Angels announced it had invested $475,000 in the round, and today Wasatch President Josh Eckman told GenomeWeb Daily News that the financing will be used primarily to build up the firm's sales and marketing operations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.